Use of Repetitive Transcranial Magnetic Stimulation in Cancer Patients With Chemotherapy-Induced Peripheral Neuropathy

Inclusion Criteria:

* have completed oxaliplatin-, paclitaxel-, or docetaxel-based chemotherapy for at least 3 months;
* complain of persistent symptoms associated with CIPN such as numbness, tingling, burning, or pain with scores ≥ 4 on a numerical rating scale for average daily intensity (0-10, with 10 being the worst) and/or determined as grade 2 or higher CIPN by oncologist according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0 (2017);
* with decreased vibration and/or pinprick sensations according to neurological test (provided by the doctoral researcher when patients was referred by their oncologists);
* have a Karnofsky Performance Score ≥ 70;
* can travel to the research hospitals for receiving the study intervention.

Exclusion Criteria:

* having brain tumor or brain metastasis;
* having pregnancy;
* having implanted medical devices;
* having history of epilepsy, brain lesion, head trauma, neurosurgical procedures, or intracranial hypertension;
* having a diagnosis of psychiatric disorder (e.g. bipolar, ongoing major depression, or schizophrenia) and/or treating with antipsychotic drugs;
* having preexisting peripheral neuropathy before initiation of chemotherapy; g) withdrawing from alcohol or sedative medications;
* having a life expectancy less than six months;
* treating with naloxone, which can block analgesic effect of rTMS over M1;
* previously treated with rTMS. Patients receiving any other treatment for CIPN may not be excluded, but they will be required not to change the type and dosage of the current treatments. Furthermore, such information will be collected as baseline clinical data and will be treated as confounding factors during data analysis.